$HROW News

Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half

Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study

Harrow: The Q2 Turnaround Is Enough For A Cautious Buy

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

BTIG Reiterates Buy on Harrow, Maintains $63 Price Target

Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $348.468M Est

Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M Estimate

BTIG Reiterates Buy on Harrow, Maintains $63 Price Target

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To Lucentis

Harrow Presents Three Studies Supporting IHEEZO, Low Viscosity Ocular Anesthetic Gel, And BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTIS At ASRS 2026 Annual Meeting

Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis

GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1

Is Harrow, Inc. (HROW) A Good Stock To Buy Now?

Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare